Nuclear medicine in the era of genomics and proteomics: Lessons from annexin V

被引：16

作者：

Belhocine, TZ

Tait, JF

Vanderheyden, JL

Li, C

Blankenberg, FG

机构：

[1] Jules Bordet canc Inst, Dept Nucl Med, B-1000 Brussels, Belgium

[2] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA

[3] Univ Washington, Dept Med Med Genet, Seattle, WA 98195 USA

[4] Univ Washington, Dept Pathol, Seattle, WA 98195 USA

[5] N Amer Sci, Theseus Imaging Corp, Boston, MA USA

[6] Univ Texas, MD Anderson Canc Ctr, Dept Mol Imaging, Houston, TX 77030 USA

[7] Stanford Univ, Sch Med, Div Radiol, Palo Alto, CA 94304 USA

来源：

JOURNAL OF PROTEOME RESEARCH | 2004年 / 3卷 / 03期

关键词：

annexin V; recombinant human; radiolabeling; apoptosis;

D O I：

10.1021/pr049968a

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

In the past decade, genomics and proteomics have begun to develop many new targets for potential diagnostic and therapeutic agents. Among the life sciences, nuclear medicine is also deeply involved in the field of clinical investigation. Experience with radiolabeled annexin V highlights the many steps required to translate a good basic-science concept into the clinical setting. This model also emphasizes the value of synergy between basic and medical specialties in developing and optimizing a clinically useful product initially derived from basic investigation.

引用

页码：345 / 349

页数：5

共 69 条

[1] Proteome and proteomics: New technologies, new concepts, and new words [J].